Literature DB >> 11390460

The frequency of high avidity T cells determines the hierarchy of determinant spreading.

J Tian1, S Gregori, L Adorini, D L Kaufman.   

Abstract

Autoimmunity often spreads in a predefined pattern during the progression of T cell-mediated autoimmune diseases. This progression has been well described in animal models and in man, but the basis for this phenomenon is little understood. To gain insight into the factors that determine this spreading hierarchy, we characterized the binding affinity of a panel of beta cell-autoantigenic peptides to I-Ag7, as well as the precursor frequency, functional avidity, and phenotype of the T cells that recognize these peptides in type 1 diabetes-prone nonobese diabetic mice. We observed that autoimmunity gradually spreads from a beta cell determinant, which had the largest precursor pool of high avidity T cells, to beta cell determinants with progressively smaller and lower avidity T cell precursor pools. This correlation between the sequential development of spontaneous T cell autoimmunity and the frequency and avidity of autoantigen-reactive T cells suggests that the extent to which T cells were negatively selected by the self-determinants is the key factor determining the spreading hierarchy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11390460     DOI: 10.4049/jimmunol.166.12.7144

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

1.  microRNAs at the regulatory frontier: an investigation into how microRNAs impact the development and effector functions of CD4 T cells.

Authors:  Erik Allen Lykken; Qi-Jing Li
Journal:  Immunol Res       Date:  2011-04       Impact factor: 2.829

Review 2.  Targeting T lymphocytes for immune monitoring and intervention in autoimmune diabetes.

Authors:  Roberto Mallone; Gerald T Nepom
Journal:  Am J Ther       Date:  2005 Nov-Dec       Impact factor: 2.688

3.  Functional avidity directs T-cell fate in autoreactive CD4+ T cells.

Authors:  Roberto Mallone; Sharon A Kochik; Helena Reijonen; Bryan Carson; Steven F Ziegler; William W Kwok; Gerald T Nepom
Journal:  Blood       Date:  2005-07-19       Impact factor: 22.113

4.  Parameters influencing antigen-specific immunotherapy for Type 1 diabetes.

Authors:  Bo Wang; Roland Tisch
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

5.  Parameters influencing antigen-specific immunotherapy for type 1 diabetes.

Authors:  Bo Wang; Roland Tisch
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

6.  Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia.

Authors:  Tetsuya Nishida; Michael Hudecek; Ana Kostic; Marie Bleakley; Edus H Warren; David Maloney; Rainer Storb; Stanley R Riddell
Journal:  Clin Cancer Res       Date:  2009-06-30       Impact factor: 12.531

Review 7.  Mechanisms of diabetic autoimmunity: II--Is diabetes a central or peripheral disorder of effector and regulatory cells?

Authors:  Nadir Askenasy
Journal:  Immunol Res       Date:  2016-02       Impact factor: 2.829

8.  Collagen-specific T-cell repertoire in blood and synovial fluid varies with disease activity in early rheumatoid arthritis.

Authors:  Francesco Ria; Romina Penitente; Maria De Santis; Chiara Nicolò; Gabriele Di Sante; Massimiliano Orsini; Dario Arzani; Andrea Fattorossi; Alessandra Battaglia; Gian Franco Ferraccioli
Journal:  Arthritis Res Ther       Date:  2008-11-17       Impact factor: 5.156

9.  Antigen-based therapy for the treatment of type 1 diabetes.

Authors:  Jide Tian; Daniel L Kaufman
Journal:  Diabetes       Date:  2009-09       Impact factor: 9.461

10.  Transgenically induced GAD tolerance curtails the development of early beta-cell autoreactivities but causes the subsequent development of supernormal autoreactivities to other beta-cell antigens.

Authors:  Jide Tian; Hoa Dang; Harald von Boehmer; Elmar Jaeckel; Daniel L Kaufman
Journal:  Diabetes       Date:  2009-09-09       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.